Jan E.E. Keunen

TL;DR: The purpose of this review is to describe this spectrum of phenotypes, which includes Best vitelliform macular dystrophy and adult-onset foveomacular viteLLiform Dystrophy, autosomal dominant vitreoretinochoroidopathy, the MRCS (microcornea, rod-cone dystrohy, cataract, posterior staphyloma) syndrome, and autosomal recessive bestrophinopathy.

TL;DR: A comprehensive overview of the current rationale and evidence with respect to the variety of interventions available for treating central serous chorioretinopathy, including pharmacology, laser treatment, and photodynamic therapy is provided.

TL;DR: An overview is presented of the broad spectrum of clinical phenotypes caused by human peripherin/RDS gene mutations, ranging from various macular dystrophies to widespread forms of retinal dystrophy such as retinitis pigmentosa.

TL;DR: It is demonstrated that visual impairment is associated with axial length and spherical equivalent and may be unavoidable at the most extreme values in this population and predicted rates of visual impairment specifically for persons with myopia.

TL;DR: Half-dose PDT is superior to HSML for treating patients with chronic central serous chorioretinopathy, leading to a significantly higher proportion of patients with complete resolution of SRF and functional improvement.